Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy - Top-Institutions - MDSpire

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy

  • By

  • Wolfgang M. Thaiss

  • Simone Moser

  • Tobias Hepp

  • Stephan Kruck

  • Steffen Rausch

  • Marcus Scharpf

  • Konstantin Nikolaou

  • Arnulf Stenzl

  • Jens Bedke

  • Sascha Kaufmann

  • August 4, 2022

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiology
    • Urologic Oncology
    • Prostate Cancer Imaging

  • #2

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Radiology
    • Oncology
    • Cancer Imaging Research

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiology
    • Urology
    • Prostate Cancer Imaging

  • #4

    Memorial University of Newfoundland - Prostate Cancer Research Centre
    Memorial University of Newfoundland - Prostate Cancer Research Centre

    St. John's, NL

    Key Differentiators

    • Radiology
    • Urology
    • Prostate Cancer Research

  • #5

    University of Cambridge - Department of Radiology
    University of Cambridge - Department of Radiology

    Cambridge, England

    Key Differentiators

    • Radiology
    • Oncology
    • Prostate Imaging

Original Source(s)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy

  • by Wolfgang M. Thaiss, Simone Moser, Tobias Hepp, Stephan Kruck, Steffen Rausch, Marcus Scharpf, Konstantin Nikolaou, Arnulf Stenzl, Jens Bedke, Sascha Kaufmann

  • August 4, 2022

Related Content

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value

Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study